Ajay Kumar Gopal MD

Hematologic Oncology

Professor, Medicine, University of Washington School of Medicine: Member, Fred Hutchinson Cancer Research Center; Clinical Research Director- Hematologic Malignancies- Seattle Cancer Care Alliance

Join to view full profile

Seattle Cancer Care Alliance (UW/FHCRC)825 Eastlake Avenue EastSeattle, WA 98109
Phone+1 206-606-1000

Dr. Gopal is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Gopal's full profile Already have an account?

Summary

Dr. Ajay Gopal is an oncologist based in Seattle, WA, with subspecialty training in hematologic oncology. He completed his medical education at Emory University School of Medicine, followed by an internal medicine residency at Duke University Hospital and a fellowship in hematology and medical oncology at the University of Washington/ Fred Hutchinson Cancer Center. His expertise lies in hematologic oncology-specifically lymphoma. Dr. Gopal has been let numerous clinical trials with over 200 publications in the field and leads the lymphoma research program at UW/Fred Hutch. He holds the Stephen H. Petersdorf Endowed Chair at the University of Washington and is a Professor at both the UW and Fred Hutch.

Education & Training

University of WashingtonFellowship, Hematology and Medical Oncology, 1997 - 2000
Duke University HospitalResidency, Internal Medicine, 1993 - 1996
Emory University School of MedicineClass of 1993

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

WA State Medical License 1997 - 2028
NC State Medical License 1996 - 1998
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014

Clinical Trials

Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies Start of enrollment: 2003 Aug 01
Completed
Phase 2
Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Start of enrollment: 1999 Feb 01
Completed
Phase 2
Iodine I 131 Tositumomab Followed by Autologous Stem Cell Transplantation in Treating Older Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Start of enrollment: 1999 Oct 01
Completed
Phase 2

Publications & Presentations

PubMed

Autologous transplant for patients with chemotherapy-sensitive late relapse of diffuse large B-cell lymphoma.
Lorenzo Iovino, Ningxin Ma, Mohamed A Kharfan-Dabaja, Alex F Herrera, Craig S Sauter
Blood Neoplasia. 2026-08-01
Incidence and clinical impact of absolute lymphocyte count-only progression in chronic lymphocytic leukemia.
Xiancheng Wu, Mazyar Shadman, Jenna M Voutsinas, Daniel S Hippe, Timothy Randolph
Blood Advances. 2026-07-16
Pharmacologic activity, safety, and preliminary efficacy of GEN3009, a CD37-targeting DuoHexaBody, in relapsed or refractory B-cell non-Hodgkin's lymphoma.
Farrukh T Awan, Joshua T Gamse, Marije B Overdijk, Esther C W Breij, Maria Jure-Kunkel
Journal for Immunotherapy of Cancer. 2026-07-07

Journal Articles

Translating Anti-CD19 CAR T-cell Therapy into Clinical Practice for relapsed/refractory Diffuse Large B-cell Lymphoma
Mazyar Shadman, Ajay K Gopal, Victor A Chow, Blood

Abstracts/Posters

AG-636 for the Treatment of Adults with Advanced Lymphoma: Initiation of a Phase 1 Clinical Study
Ajay K. Gopal, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Relapsed or Refractory CLL after CD19-Specific CAR-T Therapy: Treatment Patterns and Clinical Outcomes
Ajay K. Gopal, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Impact of Lab Abnormalities at the Time of Progression in Patients Receiving CD19-Specific CAR T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphomas
Ajay K. Gopal, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

Indolent Lymphomas: The Marathon Has a New Course
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Prolonged Lenalidomide Therapy in Multiple Myeloma Patients Does Not Impact Autologous PBSC Mobilization: A Single Center Retrospective Analysis
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Outcomes of Patients with Large B-Cell Lymphomas and Progressive Disease Following CD19-Specific CAR T-Cell TherapyClinically Relevant Abstract
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

Dr. Ajay Gopal Named Stephen H. Petersdorf Endowed Chair in Cancer Care at UW MedicineJanuary 26th, 2023
DLBCL: PFS but No OS Benefit with Polatuzumab-Vedotin Add-OnDecember 17th, 2021
Ibrutinib Add-on 'Almost Certainly' Saves Lives in DLBCLNovember 4th, 2021

Grant Support

Radioimmunotherapy For LymphomaNational Cancer Institute2011
Radiolabeled Antibody Therapy Of B-Cell LymphomaNational Cancer Institute2005–2009
Proapoptotic Therapy For B-Cell NON Hodgkin'S LymphomaNational Cancer Institute2006–2007
Optimizing Radioimmunotherapy For NON Hodgkin'S LymphomaNational Cancer Institute2000–2005